ROS1 Revealed: A Cancer Conversation on the Changing Tide of NSCLC Treatment

Gain a deeper understanding of ROS1-positive NSCLC, including its biology and pathophysiology, mechanisms of resistance that limit therapy efficacy, and the newly approved or emerging ROS1-targeted treatment options available to this patient population through podcasts, downloadable slides with notes, and an expert-written ClinicalThought commentary.

Share

Program Content

Activities

ROS1 Altered NSCLC
ROS1 Revealed: A Cancer Conversation on the Changing Tide of NSCLC Treatment
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: August 27, 2024

Expires: August 26, 2025

Activities

ROS1 in NSCLC
ROS1-Alterations and Molecular Testing in Advanced NSCLC
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: August 29, 2024

Expires: August 28, 2025

Faculty

cover img faculity

Jessica J Lin, MD

Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Alice Shaw, MD, PhD

Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Bristol-Myers Squibb.

Bristol Myers Squibb